Markets:

Overview

News

Currencies

International

Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

5.775 -0.065 (-1.11%)

Streaming Delayed Price Updated: 12:24 PM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

August 08, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

July 18, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

Three (3) Stocks Under $10 That Insiders Are Buying

July 05, 2023

These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI.

Via MarketBeat

Topics Artificial Intelligence

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

June 26, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

Earnings Preview: DiaMedica Therapeutics ↗

May 12, 2023

Via Benzinga

DiaMedica Therapeutics's Earnings Outlook ↗

March 27, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023 ↗

June 22, 2023

Via Benzinga

DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199 ↗

June 21, 2023

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a

Via Benzinga

DiaMedica Therapeutics Announces $37.5 Million Private Placement

June 21, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

June 21, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

May 30, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

May 15, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

May 08, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

April 11, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

March 28, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

March 20, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 13, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

March 06, 2023

From DiaMedica Therapeutics Inc.

Via Business Wire

$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying ↗

December 02, 2022

The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

November 09, 2022

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

November 07, 2022

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

October 31, 2022

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Provides Update on ReMEDy2 Trial

October 26, 2022

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

September 14, 2022

From DiaMedica Therapeutics Inc.

Via Business Wire

Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday ↗

October 28, 2022

Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also...

Via Benzinga

Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday ↗

October 07, 2022

Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday.

Via Benzinga

DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference

September 06, 2022

From DiaMedica Therapeutics Inc.

Via Business Wire

Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

October 06, 2022

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of...

Via Benzinga

DiaMedica Therapeutics: Q2 Earnings Insights ↗

August 10, 2022

DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:30 PM. Here's what investors need to know about the announcement.

Via Benzinga

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

August 10, 2022

From DiaMedica Therapeutics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.